FDA Brief

Warning letters Drugs

FDA warning letter to

Clinical Resolution Laboratory Inc.

High riskIssued Mar 1, 2022Posted Apr 26, 2022Division of Pharmaceutical Quality Operations IV

FDA warned Clinical Resolution Laboratory in Brea, CA, about CGMP failures and unapproved OTC drugs.

What happened

FDA inspected the Brea, California drug manufacturing facility from April 6 to April 27, 2021. It found no documented process validation, inadequate cleaning validation for shared equipment, release of an OTC topical batch before final lab testing, and an inadequate quality unit. FDA also found several OTC products marketed as skin bleaching, anorectal, external analgesic or antifungal drugs without approved applications.

What FDA found

  1. The company lacked documented validation of its manufacturing processes for its OTC drug products.

    21 CFR 211.100(a)
  2. It did not validate cleaning of shared manufacturing equipment, including microbiological testing.

    21 CFR 211.67(b)
  3. It released an OTC topical drug lot before final contract lab testing for active ingredient strength and microbiological quality was reported.

    21 CFR 211.165(a)
  4. Its quality unit lacked procedures, training, investigations, complaint handling and contract lab quality agreements.

    21 CFR 211.22
  5. Several products were unapproved new drugs because they were marketed for uses not covered by OTC monographs or lacked approved applications.

    FD&C Act section 505(a), 21 U.S.C. 355(a)
  6. The products were also misbranded under section 502(ee).

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)

What FDA wants

FDA tells the company to provide detailed corrective action plans, validation and cleaning protocols, batch reviews, and an independent assessment of its quality unit, and recommends engaging a CGMP consultant. It asks for these responses in writing; the provided letter excerpt does not state a response deadline.

Who should pay attention

  • brands that buy OTC topical products from this contract manufacturer
  • companies using shared equipment for drugs and cosmetics
  • quality teams managing contract labs and supplier quality agreements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk